Comparison of serum responses in swine after vaccination and challenge exposure with Actinobacillus pleuropneumoniae serotype 1

Douglas L. Stine From the Department of Veterinary Biomedical Sciences, University of Nebraska, INRA, Lincoln, NE 68583-0905.

Search for other papers by Douglas L. Stine in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Paula J. Fedorka-Cray From the Department of Veterinary Biomedical Sciences, University of Nebraska, INRA, Lincoln, NE 68583-0905.

Search for other papers by Paula J. Fedorka-Cray in
Current site
Google Scholar
PubMed
Close
 PhD
,
Michael J. Huether From the Department of Veterinary Biomedical Sciences, University of Nebraska, INRA, Lincoln, NE 68583-0905.

Search for other papers by Michael J. Huether in
Current site
Google Scholar
PubMed
Close
 MS
,
Martha J. Gentry From the Department of Veterinary Biomedical Sciences, University of Nebraska, INRA, Lincoln, NE 68583-0905.

Search for other papers by Martha J. Gentry in
Current site
Google Scholar
PubMed
Close
 PhD
, and
G. A. Anderson From the Department of Veterinary Biomedical Sciences, University of Nebraska, INRA, Lincoln, NE 68583-0905.

Search for other papers by G. A. Anderson in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Summary

Clinical trials have shown that currently available commercial vaccines against porcine pleuropneumonia provide inconsistent, serotype-specific protection from the disease. Recovery from naturally acquired infection, however, provides solid, serotype cross-protective immunity. We examined various serum responses of pigs receiving 1 of 4 commercial vaccines or a cell extract, and compared the serologic responses of these pigs after challenge exposure with virulent Actinobacillus pleuropneumoniae serotype 1. Evaluation of serum included complement-mediated killing, opsonizing capacity, IgG titers to whole organisms, and cytotoxin neutralization titers. Pigs that received the cell extract had fewer clinical signs of pleuropneumonia than pigs in other vaccinated groups, and also were significantly (P< 0.05) better protected from development of lung lesions and death. Such vaccinates were the only pigs that developed significant (P< 0.05) serum antibody titers (ie, protective immune response) to whole-cell antigens and to cytotoxin.

Summary

Clinical trials have shown that currently available commercial vaccines against porcine pleuropneumonia provide inconsistent, serotype-specific protection from the disease. Recovery from naturally acquired infection, however, provides solid, serotype cross-protective immunity. We examined various serum responses of pigs receiving 1 of 4 commercial vaccines or a cell extract, and compared the serologic responses of these pigs after challenge exposure with virulent Actinobacillus pleuropneumoniae serotype 1. Evaluation of serum included complement-mediated killing, opsonizing capacity, IgG titers to whole organisms, and cytotoxin neutralization titers. Pigs that received the cell extract had fewer clinical signs of pleuropneumonia than pigs in other vaccinated groups, and also were significantly (P< 0.05) better protected from development of lung lesions and death. Such vaccinates were the only pigs that developed significant (P< 0.05) serum antibody titers (ie, protective immune response) to whole-cell antigens and to cytotoxin.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 7780 7759 2267
PDF Downloads 78 72 2
Advertisement